We are upgrading the repository! The content freeze has been extended to December 11, 2024, when we expect the new repository to become available. New submissions or changes to existing items will not be allowed until after the new website goes live. All content already published will remain publicly available for searching and downloading. Updates will be posted in the Website Upgrade 2024 FAQ in the sidebar Help menu. Reach out to escholarship@umassmed.edu with any questions.

Report of the National Institutes of Health SARS-CoV-2 Antiviral Therapeutics Summit

Thumbnail
Name:
jiab305_2_.pdf
Size:
1.328Mb
Format:
PDF
Download
Authors
Hall, Matthew D.
Anderson, James M.
Schiffer, Celia A.
Conley, Anthony J.
Davis, Mindy I.
UMass Chan Affiliations
Schiffer Lab
Department of Biochemistry and Molecular Pharmacology
Document Type
Accepted Manuscript
Publication Date
2021-06-10
Keywords
SARS-CoV-2
antiviral therapeutics
emerging modalities
preclinical
proteases
viral replication machinery
Immunology of Infectious Disease
Immunotherapy
Infectious Disease
Medicinal-Pharmaceutical Chemistry

Metadata
Show full item record
Abstract
The NIH Virtual SARS-CoV-2 Antiviral Summit, held on November 6, 2020, was organized to provide an overview on the status and challenges in developing antiviral therapeutics for COVID-19, including combinations of antivirals. Scientific experts from the public and private sectors convened virtually during a live videocast to discuss SARS-CoV-2 targets for drug discovery as well as the preclinical tools needed to develop and evaluate effective small molecule antivirals. The goals of the Summit were to review the current state of the science, identify unmet research needs, share insights and lessons learned from treating other infectious diseases, identify opportunities for public-private partnerships, and assist the research community in designing and developing antiviral therapeutics. This report includes an overview of therapeutic approaches, individual panel summaries, and a summary of the discussions and perspectives on the challenges ahead for antiviral development.
Source

Hall MD, Anderson JM, Anderson A, Baker D, Bradner J, Brimacombe KR, Campbell EA, Corbett KS, Carter K, Cherry S, Chiang L, Cihlar T, de Wit E, Denison M, Disney M, Fletcher CV, Ford-Scheimer SL, Götte M, Grossman AC, Hayden FG, Hazuda DJ, Lanteri CA, Marston H, Mesecar AD, Moore S, Nwankwo JO, O'Rear J, Painter G, Saikatendu KS, Schiffer CA, Sheahan TP, Shi PY, Smyth HD, Sofia MJ, Weetall M, Weller SK, Whitley R, Fauci AS, Austin CP, Collins FS, Conley AJ, Davis MI. Report of the National Institutes of Health SARS-CoV-2 Antiviral Therapeutics Summit. J Infect Dis. 2021 Jun 10:jiab305. doi: 10.1093/infdis/jiab305. Epub ahead of print. PMID: 34111271. Link to article on publisher's site
DOI
10.1093/infdis/jiab305
Permanent Link to this Item
http://hdl.handle.net/20.500.14038/27452
PubMed ID
34111271
Notes

Full author list omitted for brevity. For the full list of authors, see article.
Related Resources

Link to Article in PubMed
Rights
This article is a work of the United States government. Such works are not entitled to domestic copyright protection under U.S. law and are therefore in the public domain.
Collections